Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02788409 · ClinicalTrials.gov registry record
Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 2,234
- Enrollment target
NCT02788409: Completed study, sponsored by Bayer.
NCT02788409 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 2,234 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02788409 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 2,234 participants
- Enrollment target
Study Summary
This study is conducted to estimate population-based incidence rates of second primary malignancies among patients with CRPC similar to those treated with Xofigo. These rates will provide context for second primary malignancy incidence rates from the REASSURE study. Furthermore this study aims to provide further information about the documentation of bone metastases in Medicare data and the extent of use of only oral androgen deprivation drugs among patients with Medicare Part D coverage, as well as to estimate overall survival of the study population.
Interventions
- OTHER Not applicable for study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,234 participants |
| Start Date | 2016-05-15 |
| Est. Completion | 2018-05-09 |
What the finished NCT02788409 record still lists
NCT02788409 is an observational study that tracks outcomes without assigning an intervention. Its 2,234 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Not applicable for study is the first listed.
NCT02788409 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02788409 about?
NCT02788409 is a clinical study titled "Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US". This study is conducted to estimate population-based incidence rates of second primary malignancies among patients with CRPC similar to those treated with Xofigo. These rates will provide context for second primary malignancy incidence rates from the REASSURE study. Furthermore this study aims to p...
What is the current status of trial NCT02788409?
This trial is currently completed. The enrollment target is 2,234 participants. The study started on 2016-05-15. Estimated completion is 2018-05-09.
What interventions are being tested in trial NCT02788409?
The interventions under investigation include: Not applicable for study (OTHER).
Who is sponsoring clinical trial NCT02788409?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06939803 · 2,236 participants · NA
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
- NCT06831929 · 2,232 participants · NA
HPV Ends Here: Increasing Uptake of the HPV Vaccine
- NCT04889872 · 2,250 participants · NA
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- NCT06805513 · 2,250 participants · Phase 3
Actual Use Trial of Tadalafil 5 mg
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI